New studies found that Americans with type 2 diabetes who are taking GLP-1 drugs like Ozempic and Mounjaro could face an ...

A study published in JAMA Network, by the Case Western Reserve University examined about 15,11,637 eligible participants with ...

One study found a modest risk of developing non-arteritic anterior ischaemic optic neuropathy (NAOIN), a rare eye condition ...

Drugs such as Ozempic, Wegovy and Mounjaro (known as semaglutide and tirzepatide) have changed the way clinicians manage ...

As weight-loss drugs are gaining popularity among Indian diabetes and obesity stricken patients in India, new research ...

New research links two widely used diabetes drugs, semaglutide or tirzepatide, to a rare but potentially vision-threatening eye condition, raising questions about drug-specific risks and the need ...

As weight loss drugs like Ozempic and Mounjaro gain a lot of attention worldwide a new study has revealed a rare side effect ...

Some studies have linked the popular weight-loss drugs with a potentially higher risk of eye problems and vision loss. Should ...

New studies indicate that weight-loss drugs may lead to serious eye diseases and vision loss in some individuals, prompting ...

A large-scale cohort study has found that GLP-1s, including Ozempic and Wegovy, may be associated with a modestly increased risk of developing diabetic retinopathy. The research, published Aug. 11 in ...

Two studies were conducted to verify concerns about diabetic retinopathy that were raised during initial trials of ...

The risk of new-onset diabetic retinopathy (DR) increased slightly, but significantly, in patients taking GLP-1 receptor ...